FDA Okays Pasireotide (Signifor LAR) for AcromegalyFDA Okays Pasireotide (Signifor LAR) for Acromegaly
The long-acting somatostatin analog pasireotide has been approved for the additional indication of treatment of acromegaly in the US, for patients who don't respond well to surgery or first-line agents. FDA Approvals
AbstractPurpose1) To compare the retinal, choroidal, Haller ’s layer, and Sattler’s/choriocapillaris thicknesses of untreated acromegaly patients without chiasm compression or diabetes mellitus and healthy controls. 2) To evaluate the correlations of retinal and choroidal thicknesses with serum growth hormone (GH) and insulin-like growth factor 1 (IGF) b urden.MethodsThis prospective, case-control study included 27 untreated acromegaly patients and 27 sex-matched and age-matched controls. Subfoveal choroidal, Haller ’s layer and Sattler’s/choriocapillaris thicknesses were determined by enhanced-dept...
According to a French study, published in theJournal of the Endocrine Society,even acromegaly patients in remission have an increased risk of developing diabetes and related metabolic disorders.Healio
Conclusion The high proliferative, but absence of non-proliferative retinopathy in our patients with acromegaly may reflect the pathogenic effect of IGF-1 on neovascularization. IGF-1 may play an important role in proliferative retinopathy, but may play no role in non-proliferative retinopathy.
Introduction: Cardiovascular diseases are main risk factor of death and disability in patient with type 2 diabetes mellitus (T2DM), acromegaly, hypercortisolism, thyrotoxicosis . Sleep apnea (SA) plays an important role in development of cardiovascular complications in patients with different endocrine disorders. Screening for sleep apnea is not included in the standards of examination of patients with endocrinopathies. The aim of study was to estimate need of sleep apnea screening in patients with endocrine disorders.
Funding Opportunity PA-18-052 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and ...
Conclusions: Switching to PAS-LAR, either as monotherapy, or combination with pegvisomant, can control IGF-I levels in the majority of patients. PAS-LAR demonstrated a pegvisomant sparing effect of 66% compared to the combination with LA-SSAs. Hyperglycemia was the most important safety issue. PMID: 29155991 [PubMed - as supplied by publisher]
ConclusionsThe results from these long-term placebo-controlled studies confirm the established safety profile of long-acting OCT, in particular low risk of cardiac, hepatic and renal toxicity in a high-risk population.
Conclusion Regarding operated cases of GH-producing pituitary adenoma, acromegaly clinical manifestations tended to be milder at diagnosis in later years of the decade, and acromegaly was diagnosed at lower IGF-1 levels and in smaller lesions. Further study is mandatory for the generalization of this trend.
ConclusionsPEGV effectiveness improves when up titration is appropriate. Higher PEGV doses at start and a more rapid up-titration are necessary in patients with obesity and/or IGF-1 > 2.7 × ULN.
ConclusionsIn experienced hands, transsphenoidal microsurgery for PAs achieves remission in most patients with a low complication rate. Pituitary function is preserved in most cases and can recover in more than one-third of patients with preoperative hypopituitarism.